MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
Robert Glenn Hubbard, a non-management director of MetLife, Inc. (MET), reported an acquisition of 916 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After this transaction, the filing shows 102,067 shares beneficially owned directly by the reporting person.
The filing notes these shares were issued as part of MetLife's non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
MetLife director Carlos M. Gutierrez acquired 534 shares of MetLife, Inc. common stock on 10/01/2025 as part of the company’s non-management director compensation program that pays a portion of retainer fees in common stock. After the purchase, Mr. Gutierrez directly owns 24,385 shares and indirectly holds 18,807 shares through the Carlos M. Gutierrez Trust. The transaction was reported on a Form 4 filed and signed via attorney-in-fact on 10/03/2025.
MetLife director William E. Kennard reported an acquisition of 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction, the reporting person beneficially owned 44,452 shares. The filing notes these shares were part of non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Some shares are held indirectly through the MetLife Policyholder Trust, which holds shares allocated to eligible policyholders of a MetLife subsidiary.
Johnson Jeh C., a non-management director of MetLife, Inc. (MET), reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction the reporting person beneficially owns 7,372 shares. The shares were paid as part of non-management director retainer fees and the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.
Denise M. Morrison, identified as a director of MetLife, Inc. (MET), reported a non-derivative acquisition of 534 shares of MetLife common stock on 10/01/2025. The shares were issued as part of MetLife's non-management director compensation and recorded with a price of $0 (retainer paid in stock). Following the transaction the reporting person beneficially owned 33,351 shares. The Form 4 filing was signed on 10/03/2025 by an attorney-in-fact. The disclosure states these shares represent a portion of the director retainer paid in company stock.
Form 144 notice for MetLife, Inc. (MET) reports a proposed sale of 333 shares of common stock, with an aggregate market value of $27,429.21, intended for sale on 10/01/2025 on the NYSE. The filing lists the securities' original acquisition dates: 114 shares purchased 06/20/2014 and 219 shares purchased 12/19/2014, both bought from GOLDMAN SACHS and paid in cash. The filing also discloses multiple sales of MetLife common stock by MetLife-related accounts during the past three months, including transactions on 07/28/2025, 07/31/2025 and 09/19/2025 with amounts and gross proceeds specified. Certain filer contact and CIK fields appear blank in the provided content.
MetLife, Inc. disclosed preliminary, unaudited estimates that its variable investment income for the quarter ended September 30, 2025 is expected to meet the company’s quarterly target of $425 million (pre-tax). This target is presented in the context of full-year 2025 guidance of approximately $1.7 billion (pre-tax) for variable investment income, which includes returns from private equity, real estate and other funds and prepayment fees. The company notes these figures are estimated and prepared in good faith on a basis consistent with prior periods but financial closing procedures are not complete and actual results could be materially different. These preliminary results are not substitutes for audited GAAP financial statements and are not necessarily indicative of future periods.
MetLife, Inc. (MET) filed a Form 144 proposing the sale of 269 shares of Common Stock through Bernstein Institutional Services on 09/19/2025, with an aggregate market value of $21,269.83. The shares were acquired on 06/20/2014 from GOLDMAN SACHS and payment was made in cash on 06/25/2014. The filing reports 665,026,054 shares outstanding for the issuer. The document also discloses multiple recent sales by MetLife-related accounts in June and July 2025, including 547 shares sold on 06/20/2025 and 1,024 shares sold on 06/27/2025, showing routine plan and separate-account transactions.
MetLife, Inc. (MET) filed a Form 144 reporting a proposed sale of 221 shares of common stock through Bernstein Institutional Services LLC with an aggregate market value of $17,474.47. The notice lists the company’s outstanding shares as 665,026,054 and an approximate sale date of 09/19/2025. The shares were originally acquired on 05/29/2015 in a purchase from Goldman Sachs with cash payment on 06/03/2015. The filing also discloses several recent sales by MetLife-related accounts between 06/20/2025 and 07/31/2025 totaling multiple transactions and varying gross proceeds.
MetLife, Inc. (MET) filed a Form 144 reporting a proposed sale of 17 shares of common stock through Bernstein Institutional Services LLC with an aggregate market value of $1,344.19. The filing lists the approximate sale date as 09/19/2025 and shows 665,026,054 shares outstanding. The 17 shares were acquired on 10/11/2021 in a purchase from Citigroup Global Markets with payment completed in cash on 10/13/2021. The filing also discloses prior sales by related MetLife accounts over the past three months totaling 2,628 shares for gross proceeds of $208,112.38. The notice includes the standard representation that the seller knows of no undisclosed material adverse information.